232 related articles for article (PubMed ID: 12679704)
1. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use.
Palepu A; Tyndall M; Yip B; O'Shaughnessy MV; Hogg RS; Montaner JS
J Acquir Immune Defic Syndr; 2003 Apr; 32(5):522-6. PubMed ID: 12679704
[TBL] [Abstract][Full Text] [Related]
2. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
3. Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy.
Palepu A; Tyndall MW; Li K; Yip B; O'Shaughnessy MV; Schechter MT; Montaner JS; Hogg RS
J Urban Health; 2003 Dec; 80(4):667-75. PubMed ID: 14709714
[TBL] [Abstract][Full Text] [Related]
4. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
CMAJ; 2003 Sep; 169(7):656-61. PubMed ID: 14517122
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with optimal pharmacy refill adherence for antiretroviral medications and plasma HIV RNA non-detectability among HIV-positive crack cocaine users: a prospective cohort study.
Hayashi K; Wood E; Kerr T; Dong H; Nguyen P; Puskas CM; Guillemi S; Montaner JS; Milloy MJ
BMC Infect Dis; 2016 Aug; 16(1):455. PubMed ID: 27568002
[TBL] [Abstract][Full Text] [Related]
6. Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting.
Krüsi A; Milloy MJ; Kerr T; Zhang R; Guillemi S; Hogg R; Montaner J; Wood E
Antivir Ther; 2010; 15(5):789-96. PubMed ID: 20710061
[TBL] [Abstract][Full Text] [Related]
7. Relationship between hunger, adherence to antiretroviral therapy and plasma HIV RNA suppression among HIV-positive illicit drug users in a Canadian setting.
Anema A; Kerr T; Milloy MJ; Feng C; Montaner JS; Wood E
AIDS Care; 2014 Apr; 26(4):459-65. PubMed ID: 24015838
[TBL] [Abstract][Full Text] [Related]
8. Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting.
Nolan S; Milloy MJ; Zhang R; Kerr T; Hogg RS; Montaner JS; Wood E
AIDS Care; 2011 Aug; 23(8):980-7. PubMed ID: 21480010
[TBL] [Abstract][Full Text] [Related]
9. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort.
Kuyper LM; Wood E; Montaner JS; Yip B; O'connell JM; Hogg RS
J Acquir Immune Defic Syndr; 2004 Dec; 37(4):1470-6. PubMed ID: 15602125
[TBL] [Abstract][Full Text] [Related]
10. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
11. Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: a longitudinal analysis.
Azar P; Wood E; Nguyen P; Luma M; Montaner J; Kerr T; Milloy MJ
BMC Infect Dis; 2015 Apr; 15():193. PubMed ID: 25927573
[TBL] [Abstract][Full Text] [Related]
12. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
[TBL] [Abstract][Full Text] [Related]
13. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
[TBL] [Abstract][Full Text] [Related]
14. The impact of illicit drug use and substance abuse treatment on adherence to HAART.
Hicks PL; Mulvey KP; Chander G; Fleishman JA; Josephs JS; Korthuis PT; Hellinger J; Gaist P; Gebo KA;
AIDS Care; 2007 Oct; 19(9):1134-40. PubMed ID: 18058397
[TBL] [Abstract][Full Text] [Related]
15. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.
Rodríguez-Arenas MA; Jarrín I; del Amo J; Iribarren JA; Moreno S; Viciana P; Peña A; Sirvent JL; Vidal F; Lacruz J; Gutierrez F; Oteo JA; Asencio R; Castilla J; Hoyos SP;
AIDS Res Hum Retroviruses; 2006 Aug; 22(8):715-23. PubMed ID: 16910826
[TBL] [Abstract][Full Text] [Related]
16. Age, adherence and injection drug use predict virological suppression among men and women enrolled in a population-based antiretroviral drug treatment programme.
O'Connell JM; Braitstein P; Hogg RS; Yip B; Craib KJ; O'Shaughnessy MV; Montaner JS; Burdge DR
Antivir Ther; 2003 Dec; 8(6):569-76. PubMed ID: 14760890
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
[TBL] [Abstract][Full Text] [Related]
18. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival.
Mocroft A; Madge S; Johnson AM; Lazzarin A; Clumeck N; Goebel FD; Viard JP; Gatell J; Blaxhult A; Lundgren JD
J Acquir Immune Defic Syndr; 1999 Dec; 22(4):369-78. PubMed ID: 10634199
[TBL] [Abstract][Full Text] [Related]
19. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with antiretroviral medication adherence among HIV-positive adults accessing highly active antiretroviral therapy (HAART) in British Columbia, Canada.
O'Neil CR; Palmer AK; Coulter S; O'Brien N; Shen A; Zhang W; Montaner JS; Hogg RS
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(2):134-41. PubMed ID: 22318879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
